Clinical Trial Update: Pembrolizumab and Decitabine for Refractory or Relapsed Acute Myeloid Leukemia [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial assessing pembrolizumab with decitabine in relapsed or refractory acute myeloid leukemia has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Decitabine (Decitabine)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: National Heart, Lung, and Blood Institute (NHLBI) | Conditions: Relapsed Acute Myeloid Leukemia | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2020-05-21